Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer*
References (24)
- et al.
Total prostatectomy for localized prostatic cancer
J Urol 131
(1984) - et al.
Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally confined extensive prostate cancer
J Urol
(1992) - et al.
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
J Urol
(1994) Anatomic considerations in carcinoma of the prostate
Urol Clin North Am
(1989)- et al.
Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup
J Urol
(1993) - et al.
Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years
Urol Clin North Am
(1993) - et al.
Incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
J Urol
(1994) - et al.
Recurrent prostate cancer despite undetectable prostate specific antigen
J Urol
(1992) - et al.
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
J Urol
(1994) - et al.
Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure
Int J Radiat Oncol Biol Phys
(1994)
Cited by (123)
Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy
2013, Journal of UrologyCitation Excerpt :We observed a small but significant increase in PSA in the treatment group but not the reference group, and a lower frequency of BCR in the treatment group. Overall 15% of patients in the high risk treatment group had suspected BCR, lower than the 18% to 32% recurrence rate for patients not receiving TRT after RP during a comparable followup period.19–22 Moreover, the recurrence rate was higher in the high risk treatment group than in the high risk reference group, with no men with BCR in the nonhigh risk subgroups.
Long-term oncologic outcomes after radical prostatectomy in clinically localized prostate cancer: 10-year follow-up in Korea
2020, Investigative and Clinical UrologyAssessment of biochemical recurrence of prostate cancer (Review)
2019, International Journal of Oncology
- *
Supported in part by grant CA58204 from the National Cancer Institute, U.S. Public Health Service for a SPORE in prostate cancer.
Copyright © 1997 Published by Elsevier Inc.